Does Mounjaro make you more fertile — and what should you know before trying to conceive?

The misconception: Mounjaro is a fertility drug

This is the most common misunderstanding our prescribers encounter on this topic, and it is worth correcting plainly. Mounjaro (tirzepatide) is a weight-management medicine licensed for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition. It is not a fertility treatment, has not been studied as one, and Eli Lilly has made no such claim for it. No clinical trial has tested tirzepatide specifically to improve conception rates, and the MHRA has not approved it for that purpose.

What research does show is that excess weight affects reproductive hormones in measurable ways. Elevated body fat raises oestrogen levels, disrupts the luteinising hormone pulses that trigger ovulation, and is closely associated with insulin resistance, all of which can suppress regular cycles. When those conditions improve through weight loss, ovulatory function can return. The medicine creates the weight loss; the body does the rest. That is a meaningful distinction, not a pedantic one, because it affects how you plan if conception is on your mind.

A question our prescribers hear regularly is whether patients should stay on Mounjaro while trying to become pregnant. The short answer is no. Current guidance recommends stopping treatment before trying to conceive, and a prescriber can advise on the appropriate timing based on your individual circumstances and the medicine's half-life.

How weight loss can influence hormonal and reproductive health

The connection between body weight and fertility is well established in the clinical literature, and it runs in both directions. Losing a meaningful amount of weight (even 5 to 10 percent of body weight) has been shown to improve insulin sensitivity, lower androgens in women with PCOS, and restore more regular menstrual cycles. For women where weight-related hormonal disruption is the primary barrier to conception, this matters.

Tirzepatide works as a dual GIP and GLP-1 receptor agonist, activating two gut-hormone pathways that reduce appetite, slow gastric emptying, and improve blood-sugar regulation. The NHS overview of tirzepatide's mechanism explains this clearly. The metabolic improvements that come alongside weight loss (lower insulin resistance, reduced inflammation) are what create the reproductive benefit, rather than any direct action of the drug on reproductive organs.

PCOS is worth naming specifically, because it sits at the intersection of weight, insulin resistance, and fertility disruption. It is one of the most common causes of irregular ovulation in women of reproductive age. Reducing weight and insulin resistance can meaningfully improve cycle regularity in this group, though results vary considerably between individuals, and PCOS has multiple components beyond weight alone. If this applies to you, a conversation with both your prescriber and a reproductive specialist is the right next step, not a change to your treatment plan made quietly at home.

Contraception, conception, and the timing question

There is a practical issue that surprises many patients: fertility can return before you expect it to. When cycles that were suppressed by weight or hormonal imbalance begin to resume during treatment, the first ovulation can happen without warning. If pregnancy is not currently planned, reliable contraception is essential throughout Mounjaro treatment.

There is an additional, specific consideration for women on oral contraceptive pills. Because Mounjaro slows gastric emptying, it can reduce the absorption of other oral medicines taken around the same time, including the pill. NHS England's guidance on weight-management injections recommends adding a non-oral contraceptive method (such as condoms) for the first four weeks of treatment and for four weeks after every dose increase. This does not mean the pill stops working entirely, but the additional precaution is clinically advised.

If you are thinking about pregnancy in the near future, that conversation belongs in your next clinical review rather than in a self-managed pause of treatment. The question of whether Mounjaro affects fertility long-term is a related one worth reading alongside this page.

What this means in practice, and why a prescriber needs to be involved

Mounjaro is not recommended during pregnancy. The MHRA's position, aligned with the SmPC, is that women who are pregnant, planning to become pregnant, or breastfeeding should not use tirzepatide. A prescriber typically advises stopping treatment with enough lead time before actively trying to conceive, taking the drug's elimination from the body into account.

If you are currently on Mounjaro and pregnancy becomes either planned or unexpected, contact your prescriber promptly rather than waiting until your next review. The same applies if your cycle changes unexpectedly during treatment, and patients sometimes notice other unexpected physical changes too, such as finding that Mounjaro makes them wee more or noticing they need to pee more frequently than usual, both of which are worth understanding as part of the broader picture of how the medicine affects the body.

Understanding what private treatment involves is part of planning for the longer term, especially if you expect to pause and potentially restart treatment around a pregnancy. Our FAQs cover common practical questions, and the clinical team at nume includes GPhC-registered prescribers who review every consultation personally. If you have questions about Mounjaro and your reproductive plans, a free consultation is the right place to start that conversation.